EICHORCondition: Neovascular (Wet) Age-related Macular Degeneration (AMD) · Sponsor: Amgen
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Associated Retina Consultants, Ltd. - Research | Phoenix, Arizona, United States | — |
| Retina Consultants of Orange County | Fullerton, California, United States | — |
| UCSD Shiley Eye Institute, Jacobs Retina Center | La Jolla, California, United States | — |
| Jules Stein Eye Institute, UCLA | Los Angeles, California, United States | — |
| Southern California Desert Retina Consultants | Palm Desert, California, United States | — |
| Retina Consultants San Diego | Poway, California, United States | — |
| Retina Consultants of Southern California | Redlands, California, United States | — |
| Retinal Consultants Medical Group, Inc. | Sacramento, California, United States | — |
| Orange County Retina Medical Group | Santa Ana, California, United States | — |
| Miramar Eye Specialists | Ventura, California, United States | — |
| Colorado Retina Associates | Lakewood, Colorado, United States | — |
| Retina Group of New England | Waterford, Connecticut, United States | — |
+ 106 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04270747